EDITORIAL POLICY AND GENERAL INFORMATION

Reports of Practical Oncology and Radiotherapy (RPOR) is an interdisciplinary bimonthly journal, publishing original contributions in clinical oncology and radiotherapy, as well as in radiotherapy physics, techniques and radiotherapy equipment. The Journal is published by Elsevier on behalf of the Polish Society of Radiation Oncology, the Czech Society of Radiation Oncology, the Hungarian Society for Radiation Oncology, the Slovenian Society for Radiotherapy and Oncology, the Polish Study Group of Head and Neck Cancer, the Guild of Bulgarian Radiotherapists, the Portuguese Society of Radiotherapy – Oncology and affiliated with Spanish Society of Radiotherapy and Oncology, and Italian Association of Radiotherapy.

These guidelines generally follow the „Uniform Requirements for Manuscripts Submitted to Biomedical Journals" The complete document appears at http://www.icmje.org

Manuscripts should be submitted online at http://ees.elsevier.com/rpor and the instructions on the site should be closely followed. Authors may submit their manuscript and track their progress to final decision. Reviewers can download manuscripts and submit their report to the editor. All manuscripts are peer reviewed. Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, without the written consent of the copyright-holder.

Editor-in-Chief: Julian Malicki Ph.D., Professor of the University of Medical Sciences in Poznan, Poland, Director of Greater Poland Cancer Centre, 15th Garbary St. 61-866 Poznan, Poland, Tel: + 48 61 8850-700, Fax: +48 618850-801. E-mail: julian.malicki@wco.pl

EDITORIAL POLICIES

Review process. Manuscripts are evaluated on the basis that they present new insights to the investigated topic, are likely to contribute to a research progress or change in clinical practice or in thinking about a disease. It is understood that all authors listed on a manuscript have agreed to its submission.

Received manuscripts are first examined by the RPOR editors. Manuscripts with insufficient priority for publication are rejected promptly. Incomplete manuscripts not prepared in the advised style will be rejected without scientific review. The registered manuscripts are sent to independent experts for scientific evaluation.

The evaluation process usually takes 3–4 weeks. Submitted papers are accepted for publication after a positive opinion of the independent reviewers.

Permissions. Materials taken from other sources must be accompanied by a written statement from both author and publisher giving permission to RPOR for reproduction. Obtain permission in writing from at least one author of papers still in press, unpublished data, and personal communications.

Patients confidentiality. Changing the details of patients in order to disguise them is a form of data alteration. However authors of clinical papers are obliged to ensure patients privacy rights. Only clinically or scientifically important data are permitted for publishing. Therefore, if it is possible to identify a patient from a case report, illustration or paper, Editors of RPOR ask for a written consent of the patient or his/her guardian to publish their data, including photograms prior to publication.
The description of race, ethnicity or culture of a study subject should occur only when it is believed to be of strong influence on the medical condition in the study. When categorizing by race, ethnicity or culture, the names should be as illustrative as possible and reflect how these groups were assigned.

Randomised controlled trials. All randomised controlled trials submitted for publication in RPOR should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website at http://www.consort-statement.org for more information. RPOR has adopted the proposal from the International Committee of Medical Journal Editors (ICMJE) which require, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. For this purpose, a clinical trial is defined as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g. phase I trials) would be exempt. Further information can be found at http://www.icmje.org.

Ethics. Work on human beings that is submitted to RPOR should comply with the principles laid down in the Declaration of Helsinki; Recommendations guiding physicians in biomedical research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964, amended by the 29th World Medical Assembly, Tokyo, Japan, October 1975, the 35th World Medical Assembly, Venice, Italy, October 1983, and the 41st World Medical Assembly, Hong Kong, September 1989. The manuscript should contain a statement that the work has been approved by the appropriate ethical committees related to the institution(s) in which it was performed and that

subjects gave informed consent to the work. Studies involving experiments with animals must state that their care was in accordance with institution guidelines. Patients' and volunteers' names, initials, and hospital numbers should not be used.

Disclaimer. Every effort is made by the Editor-in-Chief and the Editorial Board of RPOR to see that no inaccurate or misleading data, opinion or statement appear in the Reports of Practical Oncology and Radiotherapy. However, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor, sponsor or advertiser concerned. Accordingly, the Editor-in-Chief and the Editorial Board accept no liability whatsoever for the consequences of any such inaccurate of misleading data, opinion or statement. Every effort is made to ensure that drug doses and other quantities are presented accurately. Nevertheless, readers are advised that methods and techniques involving drug usage and other treatments described in RPOR, should only be followed in conjunction with the drug or treatment manufacturer's own published literature in the readers own country.

CRITERIA FOR MANUSCRIPTS

The Editorial Board of Reports of Practical Oncology and Radiotherapy takes under consideration for publication original articles with the understanding that neither the manuscript nor any part of its essential substance, tables or figures have been published previously in a print form or electronically and are not under consideration by any other publication or electronic medium. This restriction does not apply to abstracts or press reports published in connection with scientific meetings. Copies of any closely related manuscripts should be submitted to the Editor along with the manuscript that is to be considered by RPOR.

RPOR discourages the submission of more than one article dealing with related aspects of the same study.

CATEGORIES OF ARTICLES

Accepted papers are published in the following journal sections:
- original articles (not more than 10 pages)
- review articles (not more than 8 pages)
- preliminary communications for rapid communication of preliminary data (not more than 4 pages)
- technical notes (not more than 2 pages)
- letters to the Editor for comments on recent articles (not more than 1 page)
- case reports (not more than 4 pages)

PREPARATION OF MANUSCRIPT

Submission of Articles. All manuscripts should be written in English. Either American or British spelling is acceptable, but the form used must be consistent throughout the article. Authors whose native language is not English are encouraged to have their submission checked for spelling and grammar prior to submission.

The title page should contain the author(s) name and affiliation. The name of the author will be listed according to this pattern; given name (or names), which will be always initialized, followed by the family name. Please be sure of using this convention in the submitted paper.

An abstract should be no longer than 250 words and preferably structured (include aim, briefly materials and methods, results and conclusion). At the end of the abstract, key words (not more than four) must be included to be used for indexing and bibliography searching. The paper should be subdivided into sections; typically: Introduction; Theoretical Background (if applicable); Material and Methods; Results; Discussion; Conclusions; Acknowledgments (if applicable); References; Appendix (if applicable).

Background should contain scientific rationale and the general introduction to the article.

Aim should clearly describe of the study (in case of a review) purpose of the article.

Material and methods should describe clearly the selection of observational or experimental subjects (patients or laboratory animals) including controls, such as age, gender, inclusion and exclusion criteria, (the circumstances for rejection from the study should be clearly defined), randomization and masking (blinding) method.

The protocol of data acquisition, procedures, investigated parameters, methods of measurements and apparatus should be described in sufficient detail to allow other scientists to reproduce the results. Name and references to the established methods should be given. References and brief description should be provided for methods that have been published but are not well known, whereas new or substantially modified methods should be described in detail. The reasons for using them should be provided along with the evaluation of their limitations. The drugs and other chemicals should be precisely identified including generic name, dose and route of administration.

The statistical methods should be described in detail to enable verification of the reported results.

Provide information on patient's informed consent. Studies on patients and volunteers require informed consent documented in the text of the manuscript. Where there is any unavoidable risk of breach of privacy – e.g. in a clinical photograph or in case details – the patient's written consent to publication must be obtained and copied to the journal. Information on approval of a Local Ethical Committee should also be provided.

Results should concisely and reasonably summarize the findings. Restrict tables and figures to the number needed to explain the argument of the paper and assess its support. Do not duplicate data in graphs and tables. Give numbers of observation and report exclusions or losses to observation such as dropouts from a clinical trial. Report treatment complications. The results should be presented in a logical sequence in the text, tables and illustrations. Do not repeat in the text all the data from the tables or graphs. Emphasize only important observations.

Discussion should deal only with new and/or important aspects of the study. Do not repeat in detail data or other material from the Background or the Results section. Include in the Discussion the implications of the findings and their limitations, including implications for future research. The discussion should confront the results of other investigations especially those quoted in the text.

Conclusions should be linked with the goals of the study. State new hypotheses when warranted. Include recommendations when appropriate. Unqualified statements and conclusions not completely supported by the obtained data should be avoided.

Sections, subsections and sub-subsections are numbered in Arabic. Major headings should be typed in bold face; sub-headings in italic; sub-subheadings in uppercase letters and underlined. Use double spacing after headings and subheadings. No paragraph after sub-headings. List of items may be laid with each item marked by a dot, or numbered with lowercase Roman numerals or listed with lowercase Roman letters as in example below: item one item two or i) item one ii) item two or a) item one b) item two Displayed equations should be numbered consecutively in Arabic, with the number set flush right and enclosed in parentheses.

References. References must be numbered consecutively as they are cited. References selected for publication should be chosen for their importance, accessibility, and for the „further reading" opportunities they provide. References first cited in tables or figure legends must be numbered so that they will be in sequence with references cited in the text. The style of references is that of Index Medicus. List all authors when there are six or fewer; when there are seven or more, list the first three, then „et al.". The following are sample references:

Standard journal article
Lahita R, Kluger J, Drayer DE et a al: Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide. N Engl J Med 1979; 301: 1382–85

Article with published erratum
Koffler D, Reidenberg MM: Antibodies to nuclear antigens in patients treated with procainamide or acetylprocainamide [published erratum appears in N Engl J Med 1979; 302: 322–5]. N Engl J Med 1979; 301: 1382–5.

Article in electronic form
Drayer DE, Koffler D: Factors in the emergence of infectious diseases. Emerg Infect Dis [serial online] 1995 Jan-Mar [cited 1996 Jun 5];1(1):[24 screens]. Available from: http://www.cdc.gov/ncidod/EID/eid.htm.

Article, no author given
Cancer in South Africa [editorial]. S Afr Med J 1994; 84: 15

Book, personal author(s)
Ringsven MK, Bond D: Gerontology and leadership skills for nurses. 2nd ed. Albany (NY): Delmar Publishers; 1996

Book, editor(s) as author
Norman IJ, Redfern SJ, editors: Mental health care for elderly people. New York: Churchill Livingstone; 1996

Book, Organization as author and publisher
Institute of Medicine (US). Looking at the future of the Medicaid program. Washington, The Institute, 1992.

Chapter in a book
Phillips SJ, Whisnant JP: Hypertension and stroke. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York, Raven Press, 1995. p. 465–78

Conference proceedings
Kimura J, Shibasaki H, editors: Recent advances in clinical neurophysiology. Proceedings of the 10th International Congress of EMG and Clinical Neurophysiology; 1995 Oct 15–19; Kyoto, Japan. Amsterdam: Elsevier; 1996

Conference paper
Bengtsson S, Solheim BG: Enforcement of data protection, privacy and security in medical informatics. In: Lun KC, Degoulet P, Piemme TE, Rienhoff O, editors. MEDINFO 92. Proceedings of the 7th World Congress on Medical Informatics; 1992 Sep 6–10; Geneva, Switzerland.

Avoid using abstracts or review papers as references. Unpublished observations and personal communications cannot be used as references. If essential, such material may be incorporated in the appropriate place in the text. Tables to be typed on separate sheets and numbered in order of mention with Roman numerals. All tables should be referred to in the text. A caption should be included. Illustrations to be numbered serially with Arabic numbers. All figures should be referred to in the text. Captions should be typed on a separate sheet. A detailed guide on electronic artwork is available at Artwork guidelines Artwork must be designed to fit

either a single column (84 mm wide) or the full text width of the page (175 mm). Similar images should be consistent in size. Images should be tightly cropped. Lettering used in the artwork must be consistent in size (7–10pt) and font (use Arial, Courier, Helvetica, Times or Symbol). Figures may be reduced in size for publication. Mark the appropriate position of a figure in the article. Number illustrations consecutively in the order in which they are referred to in the text, and provide a caption for each figure. Please note: Because of technical complications which can arise by converting colour figures to greyscale, please submit both black and white prints corresponding to all colour illustrations. Colour artwork will be published online.

Electronic Submission of Artwork
- Files must be in the correct format: preferably TIFF, EPS or MS Office.
- Images should be captured at the following minimum resolutions: halftones and colour (all colour must be RGB) 300 dpi; combination halftones 500 dpi; line art 1000–1200 dpi.
- Annotations to the figure, such as arrows and labels should be embedded in the electronic file.
- File names should be self-explanatory with file extension included, e.g. use filename „fig1.tif" for Figure 1 in TIFF format.
- All illustrations to be provided as separate files.

Acknowledgements. List all contributors who do not meet the criteria for authorship, such as technical assistants, writing assistants or head of department who provided only general support. Financial and other material support should be disclosed and acknowledged.

Role of the funding source. All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Conflict of interest. At the end of the text, under a subheading „Conflict of interest statement" all authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/ registrations, and grants or other funding.

Authors of research articles should disclose at the time of submission any financial arrangement they may have with a company whose product figures prominently in the submitted manuscript or with a company making a competing product. Such information will be held in confidence while the paper is under review and will not influence the editorial decision, but if the article is accepted for publication, the editors will usually discuss with the authors the manner in which such information is to be communicated to the reader.

Because the essence of reviews and editorials is selection and interpretation of the literature, RPOR expects that authors of such articles will not have any financial interest in a company (or its competitor) that makes a product discussed in the article.

RPOR policy requires that reviewers, co-editors, editorial board members reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Manuscripts must be accompanied by a cover letter signed by the first author. This must include:
1. information on prior or duplicate publication or submission elsewhere of any part of the work as defined earlier in this document;
2. a statement of financial or other relationships that might lead to a conflict of interest;
3. a statement that the manuscript has been read and approved by all the authors, that the requirements for authorship as stated earlier in this document have been met, and that each author believes the manuscript represents honest work; and
4. the name, address, and telephone number of the corresponding author, who is responsible for communicating with the other authors about revisions and final approval of the proofs.

The letter should give any additional information that may be helpful to the Editor, such as the type of article in the particular journal that the manuscript represents and whether the author would be willing to meet the cost of reproducing color illustrations. The manuscript must be accompanied by copies of any permission to reproduce published material, to use illustrations or report information about identifiable people, or to name people for their contributions.